SS 12 - GI 1: Esophago-gastric Cancer: Revisiting Radiotherapy, Investigating Immunotherapy, and Mobilizing MRD

Moderator(s)

• 

  Leila Tchelebi, MD

  Northern Westchester Hospital
  Mount Kisco, NY
• 

  Kevin Du, MD, PhD, MS

  Yale School of Medicine
  New Haven, CT

Presentations:

• 8:00 AM – 8:10 AM ET

  Long-Term Prognostic Analysis of Chemoradiotherapy vs. Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results from a Prospective Randomized Control Study
  

  Presenter: Xiaxi Qiao, MD
• 8:10 AM – 8:20 AM ET

  Combination of Radiotherapy and Nivolumab for Previously Treated Advanced Gastric Cancer (CIRCUIT Trial): 3-Years Update
  

  Presenter: Yoshiyuki Suzuki, MD, PhD – Fukushima Medical University
• 8:20 AM – 8:30 AM ET

  Personalized Minimal Residual Disease Profiling Predicts Prognosis in Esophageal Carcinoma Undergoing Definitive Radiotherapy
  

  Presenter: Lin-rui Gao, MD – Chinese Academy of Medical Sciences and Peking Union Medical College
• 8:30 AM – 8:40 AM ET

  Neoadjuvant Toripalimab plus Concurrent Chemoradiotherapy in the Locally Advanced Adenocarcinoma of Esophagogastric Junction: A Phase II Trial
  

  Presenter: Rongxu Du, MD – Beijing Cancer Hospital
• 8:40 AM – 8:50 AM ET

  Quality of Life Among Long-Term Survivors of Oesophageal Cancer Cured By Definitive Radiotherapy: A Cross-Sectional Study
  

  Presenter: Qingsong Pang, MD, PhD – Tianjin Cancer Hospital
• 8:50 AM – 9:00 AM ET

  Discussant
  

  Discussant: Abraham Wu, MD – Memorial Sloan Kettering Cancer Center